BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic (CDx) for WILSERDLY (giredestrant) in combination with everolimus. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for WILSERDLY in combination with everolimus and is

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.